In this large real-world cohort, patients initiating canagliflozin had higher observed event rates for a composite of myocardial infarction, stroke, or all-cause mortality compared with those initiating selective SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and myocardial infarction.